EVO ICL™
A phakic intraocular implant for the correction of myopia and astigmatism, placed directly behind the iris and in front of the natural crystalline lens. No corneal tissue is removed, and a central port facilitates aqueous humor flow through the lens.
The EVO lens is a reversible implant. It preserves the cornea and crystalline lens.
Core characteristics
Phakic intraocular implant, placed in the posterior chamber of the eye
Placed directly behind the iris, in front of the natural crystalline lens
No removal of corneal tissue
Central port facilitates aqueous humor flow through the lens
Reversible implant, preserving the cornea and crystalline lens
Made from a soft and flexible material, permitting insertion through a small incision
Clinically shown not to cause or worsen dry eye syndrome
Collamer® material with a UV-absorbing chromophore, providing UV protection
Collamer®
Collamer® is a poly-HEMA-based copolymer containing a UV-absorbing chromophore, which provides UV protection.
EVO ICL™ position in the posterior chamber, behind the iris and in front of the natural crystalline lens.
The ICL platform
Patient selection
The EVO/EVO+ ICL™ is indicated for phakic patients aged 21 to 60 with an anterior chamber depth of 2.8 mm or greater, to correct or reduce myopia ranging from -0.5 dioptres to -20.0 dioptres with up to 6.0 D of astigmatism. It is intended for placement in the posterior chamber of the eye.
Full indications, contraindications, warnings and precautions are in the Directions For Use. See the Important Safety Information below.
Surgery overview
This section is an overview and not a procedural guide. Physician certification is required before clinical use of the EVO/EVO+ ICL™. See the Important Safety Information below.
EVO ICL™ brochure for healthcare professionals
STAAR’s full clinical brochure, sent to you by email.
Important Safety Information
Important Safety Information for the EVO/EVO+ ICL
All physicians must complete the STAAR Surgical Visian ICL Physician Training Certification Program prior to using the EVO/EVO+ ICL in a clinical setting. Please review the EVO/EVO+ ICL Directions For Use (DFU) completely before performing a clinical procedure.
INDICATIONS: The EVO/EVO+ ICL is indicated for phakic patients 21-60 years with an anterior chamber depth (ACD) 2.8 mm or greater to correct/reduce myopia ranging from -0.5 diopters to -20.0 diopters with up to 6.0 D of astigmatism. The EVO/EVO+ ICL is intended for placement in the posterior chamber of the eye.
WARNING/PRECAUTION: Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting a lens in a patient with any of the conditions described in the DFU. Prior to surgery, physicians should inform prospective patients of possible risks and benefits associated with the EVO/EVO+ ICL.
ATTENTION: Reference the EVO/EVO+ ICL DFU for a complete listing of indications, contraindications, warnings and precautions.
Evolution Vision (Pty) Ltd is the Southern African distributor for EVO ICL™.
EVO ICL™, EVO+ ICL™ and Collamer® are trademarks of STAAR Surgical Company.